BA
KRYS icon

Bridgewater Associates’s Krystal Biotech KRYS Stock Holding History

Bridgewater Associates’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.3M Buy
54,489
+8,122
+18% +$2.43M 0.08% 203
2026
Q1 		$12M Buy
46,367
+36,352
+363% +$9.67M 0.05% 240
2025
Q4 		$2.47M Buy
10,015
+292
+3% +$61.5K 0.01% 719
2025
Q3 		$1.72M Buy
+9,723
New +$1.46M 0.01% 761

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bridgewater Associates's KRYS Position: Q2 2026 in Review

Bridgewater Associates increased its Krystal Biotech (KRYS) stake by 18% in Q2 2026, buying an estimated $2.43M and bringing the position to 54,489 shares worth $20.3M. The position accounts for 0.08% of the portfolio, ranked #203.

Bridgewater Associates first reported a position in KRYS in Q3 2025 and has held it in 4 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Bridgewater Associates held 54,489 shares of Krystal Biotech worth $20.3M as of Q2 2026.
  • Bridgewater Associates bought 8,122 Krystal Biotech shares in Q2 2026, an estimated $2.43M.
  • Krystal Biotech made up 0.08% of Bridgewater Associates's portfolio in Q2 2026, its #203 holding.
  • Bridgewater Associates first reported a position in Krystal Biotech in Q3 2025 and has held it in 4 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.